Anebulo Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANEB research report →
About the company
Anebulo Pharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
- CEO
- Richard Anthony Cunningham
- IPO
- 2021
- Employees
- 3
- HQ
- Lakeway, TX, US
Price Chart
- Market Cap
- $15.50M
- P/E
- -1.96
- P/S
- 0.00
- P/B
- 1.97
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.58%
- ROIC
- -102.66%
- Revenue
- $0 · 0.00%
- Net Income
- $-8,484,763 · -3.45%
- EPS
- $-0.25 · 21.88%
- Op Income
- $-9,223,481
- FCF YoY
- 21.52%
- 52W High
- $3.42
- 52W Low
- $0.01
- 50D MA
- $0.44
- 200D MA
- $1.26
- Beta
- -1.84
- Avg Volume
- 3.73K
Get TickerSpark's AI analysis on ANEB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 4, 25 | Lawler Joseph F. | other | 25,000 |
| Apr 4, 25 | Lawler Joseph F. | other | 13,236 |
| Apr 4, 25 | SHAH BIMAL R. | other | 25,000 |
| Apr 4, 25 | SHAH BIMAL R. | other | 6,618 |
| Apr 4, 25 | Cundy Kenneth C | other | 115,037 |
| Apr 4, 25 | Aryeh Jason | other | 25,000 |
| Apr 4, 25 | Aryeh Jason | other | 4,964 |
| Apr 4, 25 | Cunningham, Richard Anthony | other | 316,352 |
| Apr 4, 25 | Lin Kenneth | other | 25,000 |
| Apr 4, 25 | Lin Kenneth | other | 4,964 |
Our ANEB coverage
Recent articles, reports, and earnings notes.
No research on ANEB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANEB report →Similar companies
Peers in the same neighborhood.